Search Results
Your search for ,WHo matches 20839 pages
Showing 8851 - 8900Asciminib for Patients With CML After Failure of ABL Kinase Inhibitor Treatment
In a phase I trial reported in The New England Journal of Medicine, Hughes et al found that asciminib, an oral BCR-ABL1 inhibitor with a mechanism of action different from available ABL1 tyrosine kinase inhibitors, was active in patients with chronic myeloid leukemia (CML) after failure of ABL...
Screening Rates Rose Among People Aged 45–49 After Release of Updated Colorectal Cancer Guidelines
Colorectal cancer screening rates more than doubled among people aged 45 to 49 in the months after the release of updated American Cancer Society guidelines in 2018 recommending screening in that age group, according to a new study. According to the findings from Fedewa et al—published in...
FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer
On December 27, 2019, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma as detected by an FDA-approved test whose disease has not ...
Final Answers
Emily Johnston, MD, MS, thinks about death a lot. “I wish we would stop saying people ‘lost a battle’ with cancer when someone dies,” she said. Dr. Johnston specializes in pediatric oncology at Children’s of Alabama hospital. Conquering cancer, she believes, doesn’t simply mean surviving it—it...
Highlights From the 2019 ASCO Research Community Forum Annual Meeting
Researchers from around the country joined together for learning and collaboration at the 2019 ASCO Research Community Forum (RCF) Annual Meeting in September. During the meeting, Aisha Peterson Johnson, MD, MPH, MBA, of the U.S. Food and Drug Administration (FDA) Office of Compliance, delivered a...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer (WWCC) is a groundbreaking program that is committed to supporting early-career women researchers by funding research grants through Conquer Cancer®, the ASCO Foundation. Since its inception 6 years ago, the program has raised over $4 million, funded 21 Young Investigator...
ASCO and IASLC Collaborate to Improve the Quality of Lung Cancer Care in Brazil
Medical oncologists in Brazil are being encouraged to take advantage of a new measure set for assessing the quality of care they provide to patients with lung cancer. Lung cancer is one of the most prevalent and deadly types of cancer in Brazil.1 Providing a platform for health-care providers to...
Trastuzumab and Hyaluronidase-oysk for Subcutaneous Use in HER2-Positive Breast Cancer
Early in 2019, trastuzumab and the endoglycosidase hyaluronidase-oysk for subcutaneous injection was approved in the treatment of HER2-positive breast cancer.1,2 The agent is indicated for adjuvant treatment of patients with HER2-overexpressing node-positive or node-negative (estrogen...
Taking a Reasonable Approach to Treating Newly Diagnosed Multiple Myeloma
Multiple myeloma is a malignancy characterized by clonal proliferation of terminally differentiated plasma cells within the bone marrow. Although it leads to a host of different issues within the body, overall survival has steadily improved in recent years. “This is largely because of better...
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: KEYNOTE-013 and KEYNOTE-170
Findings in the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials, reported in the Journal of Clinical Oncology by Philippe Armand, MD, PhD, of DanaFarber Cancer Institute, and colleagues, indicate that pembrolizumab is active in relapsed or refractory primary mediastinal large B-cell...
Pembrolizumab vs Cetuximab Plus Chemotherapy in Recurrent or Metastatic Head/Neck Squamous Cell Cancer
As reported in The Lancet by Barbara Burtness, MD, of the Department of Medicine, Yale University School of Medicine, and colleagues, the phase III KEYNOTE-048 trial has shown improved overall survival with first-line pembrolizumab plus chemotherapy vs cetuximab plus chemotherapy among patients...
Time to Treatment Is a Priority
Dr. Smith called us on a Tuesday afternoon. “I have a patient who has an abnormal mammogram showing a large mass. I’m suspecting cancer and am referring her to you for diagnosis and treatment. She’s very anxious. I hope you can help.” We were able to get Dr. Smith’s patient in the next day for...
Novel Antibody-Drug Conjugate Shows Efficacy in Women With Pretreated, Metastatic HER2-Positive Breast Cancer
The novel antibody-drug conjugate [fam-] trastuzumab deruxtecan (T-DXd) achieved high response rates and durable responses in heavily pretreated patients with HER2-positive metastatic breast cancer, according to results of the phase II DESTINY-Breast 01 trial presented at the 2019 San Antonio...
Professor Jean-Charles Soria Appointed General Director of Gustave Roussy
In a statement from Gustave Roussy on December 16, 2019, the following news was released: “By an order, the Minister of Health and Solidarity, Madame Agnès Buzyn, appointed Professor Jean-Charles Soria as General Director of Gustave Roussy for a term of 5 years. He will assume his responsibilities...
My Dream Is That Multiple Myeloma Will One Day Be in My Past and No Longer a Part of My Future
A year before my diagnosis of multiple myeloma, in 2010, my husband Paul and I moved with our six children to Monterrey, Mexico, where Paul was helping to create a venture capital industry. We were so busy settling into a new country and getting our children integrated into school that when I...
Sequencing of Enzalutamide and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
In a Canadian phase II crossover trial reported in The Lancet Oncology, Kim N. Chi, MD, and colleagues found that time to second prostate-specific antigen (PSA) progression from start of treatment was longer with crossover from abiraterone acetate/prednisone to enzalutamide vs the reverse sequence ...
FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...
Explaining Risk Factors Related to Anal Cancer
A recent study found rising rates of squamous cell carcinoma of the anus, “particularly advanced-stage disease, and a similar rise in mortality.”1 The authors concluded: “Improved prevention strategies are urgently needed to mitigate the rising [squamous cell carcinoma of the anus] burden among a...
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With Unresectable or Metastatic HER2-Positive Breast Cancer
On December 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting....
Incidence of Squamous Cell Carcinoma of the Anus Has ‘Increased Dramatically’ in Older Women and Young Black Men
“Squamous cell carcinoma of the anus incidence has increased dramatically in elderly women and young black men,” according to a study of recent trends in incidence and mortality. “Advanced-stage [anal squamous cell carcinoma] incidence tripled with a prominent rise in … mortality,” researchers...
The Rise and Fall of Tobacco Products in the United States
It was a press conference on a cold Saturday in January 1964 that had garnered international attention, but the trappings were those of a secret government meeting, behind locked doors secured by uniformed guards. To the chagrin of the reporters, “no smoking” signs had been hastily posted around...
How Effective Is Supplemental MRI Screening for Women With Extremely Dense Breasts?
In the Dutch DENSE study reported in The New England Journal of Medicine, Bakker et al found that supplemental magnetic resonance imaging (MRI) in women with extremely dense breast tissue and normal results on screening mammography was associated with the diagnosis of significantly fewer interval...
Gilteritinib for Relapsed or Refractory AML With FLT3 Mutation
Late in 2018, the FLT3 inhibitor gilteritinib was approved for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA also approved an expanded indication...
Selected Abstracts From the 2019 ASH Annual Meeting & Exposition
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for acute myeloid leukemia (AML). For full details of these...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid ...
Pembrolizumab in Adjuvant Treatment of Melanoma With Involvement of Lymph Nodes After Complete Resection
In early 2019, pembrolizumab was approved for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.1,2 Supporting Efficacy Data Approval was based on findings in the double-blind EORTC 1325/KEYNOTE-054 trial (ClinicalTrials.gov identifier...
Long-Term Data on Brigatinib in First-Line Setting of ALK-Positive Non–Small Cell Lung Cancer
Updated data from the phase III ALTA-1L trial were presented by D. Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, during the Presidential Session at the European Society for Medical Oncology (ESMO) Asia Congress 2019 in Singapore.1 The trial evaluated brigatinib vs...
Grief Symptom Levels in Parents of Children Who Have Died of Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Pohlkamp et al identified factors associated with levels of prolonged grief symptoms in parents of children who have died of cancer, with factors being found to differ between mothers and fathers.1 As stated by the investigators,...
Coexisting With Cancer and Depression
Among the highlights at the 2019 Supportive Care in Oncology Symposium in October was the keynote address by Thomas J. Smith, MD, FACP, FASCO, FAAHPM, the Harry J. Duffey Family Professor of Palliative Medicine and Director of Palliative Medicine at Johns Hopkins Medicine and Professor of Oncology ...
Expert Point of View: Preet M. Chaudhary, MD, PhD
Preet M. Chaudhary, MD, PhD, of the University of Southern California (USC) Keck School of Medicine, Los Angeles, commented on the HOVON-96 trial for The ASCO Post. Dr. Chaudhary is Professor and Chief of Hematology, the Ronald H. Bloom Family Chair in Lymphoma Research, and Program Director of...
ACCC Project Focuses on Multidisciplinary Care of Cutaneous Squamous Cell Carcinoma
Due to the rarity of advanced cutaneous squamous cell carcinoma, staying current with the latest information on diagnosing, treating, and supporting patients with this diagnosis can be challenging for clinicians who do not often encounter it in practice. To support the multi-disciplinary cancer...
Acupuncture May Reduce Radiation-Induced Dry Mouth for Patients With Head and Neck Cancer
After receiving acupuncture treatment 3 days a week during the course of radiation treatment, patients with head and neck cancer experienced less dry mouth, according to study results published by Garcia et al in JAMA Network Open. The results are from the first randomized, placebo-controlled,...
Ashwani Rajput, MD, Named Director of Johns Hopkins Kimmel Cancer Center for Washington, DC, Region
Ashwani Rajput, MD, a surgical oncologist and researcher, has been appointed Director of the Kimmel Cancer Center at Johns Hopkins for the Washington, DC, region. Dr. Rajput assumed his new role in November 1 and is based at Sibley Memorial Hospital in Washington, DC. Dr. Rajput specializes in the ...
ASCO/NCODA Release Standards for Medically Integrated Dispensing of Oral Anticancer Drugs
ASCO and the National Community Oncology Dispensing Association (NCODA) have published recommended standards for medically integrated dispensing of oral anticancer therapies and supportive care medications in the oncology clinic.1 “The NCODA created quality standards 6 years ago and recognized the ...
ASCO’s National Cancer Opinion Survey Finds Gaps in Knowledge on Cancer Prevention and the Dangers of E-Cigarettes
As in the previous 2 years, the results from ASCO’s 2019 Cancer Opinion Survey revealed some startling answers about the public’s understanding of cancer, its risk factors, and strategies to prevent the disease. Although a majority of Americans (57%) said they were concerned about developing...
Relapsed or Refractory Multiple Myeloma Outcomes Improving Exponentially
Emerging treatments for relapsed or refractory multiple myeloma include options beyond triplet regimens, including immunotherapy and mutation-driven therapy. Several exciting drugs are poised to be available in the clinic in 2020, according to speakers at the recent JADPRO Live, the annual...
Expert Point of View: Thierry Facon, MD, and Michael Jain, MD, PhD
Thierry Facon, MD, Professor of Hematology at Lille University Hospital in France, and Michael Jain, MD, PhD, of Moffitt Cancer Center, Tampa, were interviewed by The ASCO Post on the second-generation chimeric antigen receptor (CAR) T-cell products for treating multiple myeloma. According to Dr. ...
Phase Ib/II Studies Explore Next-Generation BCMA-Targeted CAR T-Cell Therapies in Multiple Myeloma
In patients with relapsed or refractory multiple myeloma, two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses, with seemingly less cytokine-release syndrome and neurotoxicity than first-generation CAR T-cell products, according to the...
ESMO Immuno-Oncology 2019: Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC
Few grade 3 or higher immune-related adverse events were observed in patients treated with first-line durvalumab plus platinum/etoposide for extensive-stage small cell lung cancer (SCLC), according to findings from the safety analysis of the phase III CASPIAN study presented by Özgüroğlu et al at...
Does Second-Line Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Confer a Survival Benefit?
As reported in the Journal of Clinical Oncology by Richard S. Finn, MD, and colleagues, the phase III KEYNOTE-240 trial has shown no statistically significant progression-free or overall survival benefit with pembrolizumab vs placebo in patients with advanced hepatocellular carcinoma who were...
FDA Approves Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
On December 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to enfortumab vedotin-ejfv (Padcev) for adult patients with locally advanced or metastatic urothelial cancer who have previously received neoadjuvant or adjuvant treatment with a programmed cell death protein 1 ...
CancerCare to Provide Support for Patients With Cancer Impacted by the California Wildfires
As many California residents continue to deal with the aftermath of past wildfires and the advent of new ones, CancerCare is now offering a patient assistance program for both emotional and financial support to patients with cancer affected by the California fires. As a leading national nonprofit...
Veliparib/Chemotherapy Combination Active in HER2-Negative BRCA-Positive Advanced Breast Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin/paclitaxel chemotherapy significantly improved progression-free survival in patients with advanced HER2-negative breast cancer and germline BRCA mutation compared with placebo plus chemotherapy, according to...
ASTRO Issues Clinical Guideline on Radiation Therapy for Basal Cell and Cutaneous Squamous Cell Carcinomas
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with the most common types of skin cancers. The guideline details when radiation treatments are appropriate as stand-alone therapy...
Single-Fraction vs Multifraction Radiotherapy for Patients With Spine Metastases
Spinal canal compression is a common complication in patients with cancer if disease metastasizes to the spine—about 3% to 5% of patients with cancer develop it. Radiotherapy is used to control pain and alleviate symptoms. According to results from the SCORAD randomized clinical trial, published by ...
Survey of Anticipation and Experience of Adverse Effects in Patients Receiving Radiotherapy
In a study reported in the Journal of Oncology Practice, Reshma Jagsi, MD, DPhil, and colleagues found that most patients undergoing radiation therapy for cancer reported that they did not experience anticipated radiotherapy adverse effects, or that the adverse effect was no worse than expected....
Recurrence Risk in Black and White Women With Borderline Estrogen Receptor–Positive Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Benefield et al found that black women with borderline estrogen receptor (ER)-positive breast cancer had significantly poorer disease-free interval compared with those with ER-positive disease, irrespective of whether they...
Pembrolizumab in Refractory Metastatic Castration-Resistant Prostate Cancer
In the phase II KEYNOTE-199 study, reported in the Journal of Clinical Oncology by Antonarakis et al, pembrolizumab showed activity and had an acceptable safety profile in patients with treatment-refractory metastatic castration-resistant prostate cancer. Study Details The trial was conducted at 85 ...
A Systematic Approach to Identifying the Molecular Factors That Lead to Cancer Progression
Although gene mutations are the primary drivers of carcinogenesis, an array of complex and tumor-specific molecular interaction networks determine cancer cell behavior. To learn more about this line of inquiry, The ASCO Post recently spoke with Andrea Califano, Dr., Professor of Chemical Biology...
Everett E. Vokes, MD, FASCO, Elected ASCO President for 2021–2022 Term
ASCO membership has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the 2021–2022 term. He will take office as President-Elect during the ASCO Annual Meeting in June 2020. Six new members were also elected to the ASCO Board of Directors and...
